{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:14:05Z","timestamp":1788956045113,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Protein-energy wasting, sarcopenia, and anemia are common complications of chronic kidney disease (CKD) and are associated with poor outcomes. This systematic review and meta-analysis evaluated the effects of nandrolone decanoate on lean body mass and hematologic parameters in adults with CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed\/MEDLINE, CENTRAL, Embase, and LILACS up to February 18, 2026, for randomized controlled trials of intramuscular nandrolone decanoate in adults with CKD. Primary outcomes were lean body mass, hemoglobin, and hematocrit. Risk of bias and certainty of evidence were assessed using RoB 2 and GRADE, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen RCTs published between 1974 and 2021 were included. Nandrolone decanoate was associated with increased lean body mass (4 trials; n\u2009=\u2009125; MD 2.63 kg, 95% CI 1.60\u20133.65). Pooled estimates for hemoglobin (6 trials; n\u2009=\u2009239; MD 0.81 g\/dL) and hematocrit (7 trials; n\u2009=\u2009198; MD 3.12%) also favored nandrolone, but were limited by substantial heterogeneity and very low certainty of evidence, precluding firm conclusions. Quality-of-life effects were inconsistent, and long-term safety data were sparse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nandrolone decanoate was associated with increased lean body mass in adults with CKD. However, the evidence base is largely historical, and substantial heterogeneity and very low certainty of evidence preclude firm conclusions regarding hematologic benefits. Contemporary randomized trials are needed to clarify whether nandrolone has any role in current CKD management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-026-04771-9","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:24:51Z","timestamp":1788949491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of nandrolone decanoate on lean body mass and anemia in adults with chronic kidney disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6329-2897","authenticated-orcid":false,"given":"Lucas Caseri","family":"C\u00e2mara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9245-2509","authenticated-orcid":false,"given":"Diogo Pinto","family":"da Costa Viana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3418-8870","authenticated-orcid":false,"given":"L\u00facio","family":"de Sousa Monte Alto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6276-3410","authenticated-orcid":false,"given":"Samara Oliveira","family":"Mattoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2168-8927","authenticated-orcid":false,"given":"Nelson Carvas","family":"Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0371-1876","authenticated-orcid":false,"given":"Matheus Hissa Louren\u00e7o","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0710-2419","authenticated-orcid":false,"given":"Zahid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"10225","key":"4771_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"B Bikbov","year":"2020","unstructured":"B. Bikbov, C.A. Purcell, A.S. Levey et al., Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 395(10225), 709\u2013733 (2020)","journal-title":"Lancet"},{"issue":"5","key":"4771_CR2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.23876\/j.krcp.24.214","volume":"44","author":"SR Price","year":"2025","unstructured":"S.R. Price, X.H. Wang, Protein-energy wasting in chronic kidney disease: mechanisms responsible for loss of muscle mass and function. Kidney Res. Clin. Pract. 44(5), 726\u2013740 (2025)","journal-title":"Kidney Res. Clin. Pract."},{"issue":"2","key":"4771_CR3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/jcsm.13425","volume":"15","author":"MP Duarte","year":"2024","unstructured":"M.P. Duarte, L.S. Almeida, S.G.R. Neri et al., Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle. 15(2), 501\u2013512 (2024)","journal-title":"J. Cachexia Sarcopenia Muscle"},{"issue":"14","key":"4771_CR4","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jama.281.14.1275","volume":"281","author":"KL Johansen","year":"1999","unstructured":"K.L. Johansen, K. Mulligan, M. Schambelan, Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 281(14), 1275\u20131281 (1999)","journal-title":"JAMA"},{"issue":"6","key":"4771_CR5","doi-asserted-by":"crossref","first-page":"e220061","DOI":"10.1530\/EC-22-0061","volume":"11","author":"AC van der Burgh","year":"2022","unstructured":"van der A.C. Burgh, S.R. Khan, S.J.C.M.M. Neggers, E.J. Hoorn, L. Chaker, The role of serum testosterone and dehydroepiandrosterone sulfate in kidney function and clinical outcomes in chronic kidney disease: a systematic review and meta-analysis. Endocr. Connect. 11(6), e220061 (2022)","journal-title":"Endocr. Connect."},{"issue":"2","key":"4771_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.jrn.2013.01.001","volume":"23","author":"JJ Carrero","year":"2013","unstructured":"J.J. Carrero, P. Stenvinkel, L. Cuppari, T.A. Ikizler, K. Kalantar-Zadeh, G. Kaysen et al., Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J. Ren. Nutr. 23(2), 77\u201390 (2013)","journal-title":"J. Ren. Nutr."},{"issue":"22","key":"4771_CR7","doi-asserted-by":"publisher","first-page":"e15490","DOI":"10.14814\/phy2.15490","volume":"10","author":"ES Oh","year":"2022","unstructured":"E.S. Oh, C.N. Steele, Z. You, K.L. Nowak, A.J. Jovanovich, Sex hormones and the risk of cardiovascular disease and mortality in male and female patients with chronic kidney disease: a systematic review and meta-analysis. Physiol. Rep. 10(22), e15490 (2022)","journal-title":"Physiol. Rep."},{"issue":"15","key":"4771_CR8","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1056\/NEJM198104093041504","volume":"304","author":"MS Neff","year":"1981","unstructured":"M.S. Neff, J. Goldberg, R.F. Slifkin, A.R. Eiser, V. Calamia, M. Kaplan et al., A comparison of androgens for anemia in patients on hemodialysis. N Engl. J. Med. 304(15), 871\u2013875 (1981)","journal-title":"N Engl. J. Med."},{"issue":"8","key":"4771_CR9","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1681\/ASN.2006010034","volume":"17","author":"KL Johansen","year":"2006","unstructured":"K.L. Johansen, P.L. Painter, G.K. Sakkas, P. Gordon, J. Doyle, T. Shubert, Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: a randomized, controlled trial. J. Am. Soc. Nephrol. 17(8), 2307\u20132314 (2006)","journal-title":"J. Am. Soc. Nephrol."},{"issue":"3","key":"4771_CR10","doi-asserted-by":"publisher","first-page":"c125","DOI":"10.1159\/000103000","volume":"106","author":"JH Macdonald","year":"2007","unstructured":"J.H. Macdonald, S.M. Marcora, M.M. Jibani, M.J. Kumwenda, W. Ahmed, A.B. Lemmey, Nandrolone decanoate as anabolic therapy in chronic kidney disease: a randomized phase II dose-finding study. Nephron Clin. Pract. 106(3), c125\u2013c135 (2007)","journal-title":"Nephron Clin. Pract."},{"key":"4771_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/580437","volume":"2012","author":"B Adamu","year":"2012","unstructured":"B. Adamu, S.M. Ma\u2019aji, P.J. Erwin, I.M. Tleyjeh, Meta-analysis of randomized controlled trials on androgens versus erythropoietin for anaemia of chronic kidney disease: implications for developing countries. Int. J. Nephrol. 2012, 1\u20136 (2012)","journal-title":"Int. J. Nephrol."},{"issue":"2","key":"4771_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM198701083160203","volume":"316","author":"JW Eschbach","year":"1987","unstructured":"J.W. Eschbach, J.C. Egrie, M.R. Downing, J.K. Browne, J.W. Adamson, Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl. J. Med. 316(2), 73\u201378 (1987)","journal-title":"N Engl. J. Med."},{"issue":"3","key":"4771_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000455166","volume":"45","author":"F Locatelli","year":"2017","unstructured":"F. Locatelli, S. Fishbane, G.A. Block, I.C. Macdougall, Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am. J. Nephrol. 45(3), 187\u2013199 (2017)","journal-title":"Am. J. Nephrol."},{"issue":"4","key":"4771_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/sj.ki.5002585","volume":"73","author":"D Fouque","year":"2008","unstructured":"D. Fouque, K. Kalantar-Zadeh, J. Kopple, N. Cano, P. Chauveau, L. Cuppari et al., A proposed nomenclature and diagnostic criteria for protein\u2013energy wasting in acute and chronic kidney disease. Kidney Int. 73(4), 391\u2013398 (2008)","journal-title":"Kidney Int."},{"issue":"10","key":"4771_CR15","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.2215\/CJN.10261013","volume":"9","author":"N Isoyama","year":"2014","unstructured":"N. Isoyama, A.R. Qureshi, C.M. Avesani, B. Lindholm, P. B\u00e0r\u00e0ny, O. Heimb\u00fcrger et al., Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. Clin. J. Am. Soc. Nephrol. 9(10), 1720\u20131728 (2014)","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"9","key":"4771_CR16","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/ndt\/gft070","volume":"29","author":"IH Fahal","year":"2014","unstructured":"I.H. Fahal, Uraemic sarcopenia: aetiology and implications. Nephrol. Dial Transpl. 29(9), 1655\u20131665 (2014)","journal-title":"Nephrol. Dial Transpl."},{"key":"4771_CR17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow et al., The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372, n71 (2021)","journal-title":"BMJ"},{"issue":"1","key":"4771_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"M. Ouzzani, H. Hammady, Z. Fedorowicz, A. Elmagarmid, Rayyan-a web and mobile app for systematic reviews. Syst. Rev. 5(1), 210 (2016)","journal-title":"Syst. Rev."},{"key":"4771_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"J.A.C. Sterne, J. Savovi\u0107, M.J. Page, R.G. Elbers, N.S. Blencowe, I. Boutron et al., RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 366, l4898 (2019)","journal-title":"BMJ"},{"key":"4771_CR20","unstructured":"J.P.T. Higgins, J. Thomas, J. Chandler, M. Cumpston, T. Li, M.J. Page et al., Cochrane handbook for systematic reviews of interventions. version 6.5. Cochrane; 2024"},{"issue":"7109","key":"4771_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"M. Egger, G.D. Smith, M. Schneider, C. Minder, Bias in meta-analysis detected by a simple, graphical test. BMJ. 315(7109), 629\u2013634 (1997)","journal-title":"BMJ"},{"key":"4771_CR22","volume-title":"A language and environment for statistical computing","author":"R Core Team","year":"2025","unstructured":"R Core Team, A language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, 2025)"},{"key":"4771_CR23","volume-title":"RStudio: Integrated development environment for R","author":"Posit team","year":"2024","unstructured":"Posit team, RStudio: Integrated development environment for R (Posit Software, PBC, Boston, 2024)"},{"issue":"4","key":"4771_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"S. Balduzzi, G. R\u00fccker, G. Schwarzer, How to perform a meta-analysis with R: a practical tutorial. Evid. Based Ment Health. 22(4), 153\u2013160 (2019)","journal-title":"Evid. Based Ment Health"},{"issue":"4","key":"4771_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"G. Guyatt, A.D. Oxman, E.A. Akl, R. Kunz, G. Vist, J. Brozek et al., GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables. J. Clin. Epidemiol. 64(4), 383\u2013394 (2011)","journal-title":"J. Clin. Epidemiol."},{"issue":"7","key":"4771_CR26","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/archinte.1975.00330070094015","volume":"135","author":"BD Doane","year":"1975","unstructured":"B.D. Doane, W. Fried, F. Schwartz, Response of uremic patients to nandrolone decanoate. Arch. Intern. Med. 135(7), 972\u2013975 (1975)","journal-title":"Arch. Intern. Med."},{"issue":"4","key":"4771_CR27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0272-6386(97)90340-1","volume":"29","author":"JL Teruel","year":"1997","unstructured":"J.L. Teruel, M.A. Lasuncion, M. Rivera et al., Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. Am. J. Kidney Dis. 29(4), 569\u2013575 (1997)","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"4771_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0272-6386(12)80246-0","volume":"17","author":"SH Ballal","year":"1991","unstructured":"S.H. Ballal, D.T. Dornoto, D.C. Polack, P. Marciulonis, K.J. Martin, Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am. J. Kidney Dis. 17(1), 29\u201333 (1991)","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"4771_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3904\/kjim.2002.17.3.167","volume":"17","author":"MS Lee","year":"2002","unstructured":"M.S. Lee, S.H. Ahn, J.J. Song, Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low-dose recombinant human erythropoietin. Korean J. Intern. Med. 17(3), 167\u2013173 (2002)","journal-title":"Korean J. Intern. Med."},{"issue":"4","key":"4771_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/039139880102400402","volume":"24","author":"KL Johansen","year":"2001","unstructured":"K.L. Johansen, The role of nandrolone decanoate in patients with end stage renal disease in the erythropoietin era. Int. J. Artif. Organs. 24(4), 183\u2013185 (2001)","journal-title":"Int. J. Artif. Organs"},{"issue":"4","key":"4771_CR31","first-page":"232","volume":"18","author":"D Buchwald","year":"1977","unstructured":"D. Buchwald, S. Argyres, R.E. Easterling et al., Effect of nandrolone decanoate on the anemia of chronic hemodialysis patients. Nephron. 18(4), 232\u2013238 (1977)","journal-title":"Nephron"},{"issue":"1","key":"4771_CR32","first-page":"12","volume":"79","author":"LR Solomon","year":"1988","unstructured":"L.R. Solomon, E.D. Hendler, Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics. Acta Haematol. 79(1), 12\u201319 (1988)","journal-title":"Acta Haematol."},{"issue":"1","key":"4771_CR33","first-page":"1","volume":"83","author":"ED Hendler","year":"1990","unstructured":"E.D. Hendler, L.R. Solomon, Prospective controlled study of androgen effects on red cell oxygen transport and work capacity in chronic hemodialysis patients. Acta Haematol. 83(1), 1\u20138 (1990)","journal-title":"Acta Haematol."},{"issue":"3","key":"4771_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1053\/j.jrn.2007.01.001","volume":"17","author":"S Eiam-Ong","year":"2007","unstructured":"S. Eiam-Ong, S. Buranaosot, S. Eiam-Ong, A. Wathanavaha, P. Pansin, Nutritional effect of nandrolone decanoate in predialysis patients with chronic kidney disease. J. Ren. Nutr. 17(3), 173\u2013178 (2007)","journal-title":"J. Ren. Nutr."},{"issue":"2","key":"4771_CR35","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/archinte.1974.00320200099013","volume":"134","author":"JS Williams","year":"1974","unstructured":"J.S. Williams, J.H. Stein, T.F. Ferris, Nandrolone decanoate therapy for patients receiving hemodialysis: a controlled study. Arch. Intern. Med. 134(2), 289\u2013292 (1974)","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"4771_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/ki.1977.134","volume":"12","author":"DC Cattran","year":"1977","unstructured":"D.C. Cattran, S.S.A. Fenton, D.R. Wilson, D. Oreopoulos, A. Shimizu, R.M. Richardson, A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney Int. 12(6), 430\u2013437 (1977)","journal-title":"Kidney Int."},{"issue":"2","key":"4771_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1023\/A:1008306301255","volume":"9","author":"A Gasc\u00f3n","year":"1999","unstructured":"A. Gasc\u00f3n, J.J. Belvis, F. Berisa, E. Iglesias, V. Estopi\u00f1\u00e1n, J.L. Teruel, Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. Geriatr. Nephrol. Urol. 9(2), 67\u201372 (1999)","journal-title":"Geriatr. Nephrol. Urol."},{"issue":"11","key":"4771_CR38","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.53350\/pjmhs2115113296","volume":"15","author":"M Abdul Azim Baig","year":"2021","unstructured":"M. Abdul Azim Baig, I. Alam, F. Usman Sulehri, I. Hassan, A. Jafri, H. Ahmed Butt, Change in hemoglobin with androgen and low dose erythropoietin versus erythropoietin alone in patients of anemia of chronic kidney disease. Pak J. Med. Health Sci. 15(11), 3296\u20133298 (2021)","journal-title":"Pak J. Med. Health Sci."},{"issue":"4","key":"4771_CR39","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1046\/j.1523-1755.2002.00271.x","volume":"61","author":"JF Navarro","year":"2002","unstructured":"J.F. Navarro, C. Mora, M. Mac\u00eda et al., Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney Int. 61(4), 1537\u20131544 (2002)","journal-title":"Kidney Int."},{"issue":"4","key":"4771_CR40","doi-asserted-by":"publisher","first-page":"c102","DOI":"10.1159\/000083891","volume":"99","author":"H Sheashaa","year":"2005","unstructured":"H. Sheashaa, W. Abdel-Razek, A. El-Husseini, A. Selim, N. Hassan, T. Abbas et al., Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis: a prospective randomized controlled study. Nephron Clin. Pract. 99(4), c102\u2013c106 (2005)","journal-title":"Nephron Clin. Pract."},{"issue":"4","key":"4771_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S0272-6386(97)90307-3","volume":"30","author":"WJ Gaughan","year":"1997","unstructured":"W.J. Gaughan, K.A. Liss, S.R. Dunn et al., A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am. J. Kidney Dis. 30(4), 495\u2013500 (1997)","journal-title":"Am. J. Kidney Dis."},{"issue":"2","key":"4771_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00467-017-3663-y","volume":"33","author":"MA Atkinson","year":"2018","unstructured":"M.A. Atkinson, B.A. Warady, Anemia in chronic kidney disease. Pediatr. Nephrol. 33(2), 227\u2013238 (2018)","journal-title":"Pediatr. Nephrol."},{"issue":"10","key":"4771_CR43","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"J.L. Babitt, H.Y. Lin, Mechanisms of anemia in CKD. J. Am. Soc. Nephrol. 23(10), 1631\u20131634 (2012)","journal-title":"J. Am. Soc. Nephrol."},{"issue":"10191","key":"4771_CR44","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","volume":"393","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"A.J. Cruz-Jentoft, A.A. Sayer, Sarcopenia Lancet. 393(10191), 2636\u20132646 (2019)","journal-title":"Sarcopenia Lancet"},{"issue":"4","key":"4771_CR45","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jamda.2011.01.003","volume":"12","author":"RA Fielding","year":"2011","unstructured":"R.A. Fielding, B. Vellas, W.J. Evans, S. Bhasin, J.E. Morley, A.B. Newman et al., Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J. Am. Med. Dir. Assoc. 12(4), 249\u2013256 (2011)","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"1","key":"4771_CR46","doi-asserted-by":"publisher","first-page":"e13671","DOI":"10.1002\/jcsm.13671","volume":"16","author":"MV Bideshki","year":"2025","unstructured":"M.V. Bideshki, M. Behzadi, M. Jamali, P. Jamilian, M. Zarezadeh, B.P. Gargari et al., Ergogenic benefits of \u03b2-hydroxy-\u03b2-methyl butyrate (HMB) supplementation on body composition and muscle strength: an umbrella review of meta-analyses. J. Cachexia Sarcopenia Muscle. 16(1), e13671 (2025)","journal-title":"J. Cachexia Sarcopenia Muscle"},{"issue":"5","key":"4771_CR47","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1681\/ASN.2012070702","volume":"24","author":"B Roshanravan","year":"2013","unstructured":"B. Roshanravan, C. Robinson-Cohen, K.V. Patel, E. Ayers, A.J. Littman, de I.H. Boer et al., Association between physical performance and all-cause mortality in CKD. J. Am. Soc. Nephrol. 24(5), 822\u2013830 (2013)","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"4771_CR48","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/biomedicines13020352","volume":"13","author":"CC Tsai","year":"2025","unstructured":"C.C. Tsai, P.C. Wang, T. Hsiung, Y.H. Fan, J.T. Wu, W.C. Kan et al., Sarcopenia in chronic kidney disease: a narrative review from pathophysiology to therapeutic approaches. Biomedicines. 13(2), 352 (2025)","journal-title":"Biomedicines"},{"key":"4771_CR49","first-page":"711","volume-title":"Pediatric nephrology","author":"WW Cheung","year":"2010","unstructured":"W.W. Cheung, K.H. Paik, R.H. Mak, Inflammation and cachexia in chronic kidney disease, in Pediatric nephrology, ed. by E.D. Avner, W.E. Harmon, P. Niaudet, N. Yoshikawa (Springer, Berlin, 2010), pp. 711\u2013724"},{"key":"4771_CR50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/978-1-62703-685-6_13","volume-title":"Nutrition in kidney disease","author":"K Kalantar-Zadeh","year":"2014","unstructured":"K. Kalantar-Zadeh, Protein-energy wasting, in Nutrition in kidney disease, ed. by L.D. Byham-Gray, J.D. Burrowes, G.M. Chertow (Humana, Totowa, NJ, 2014), pp. 219\u2013230"},{"key":"4771_CR51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.nutos.2023.06.003","volume":"49","author":"CT Chao","year":"2023","unstructured":"C.T. Chao, Weighing the pros and cons of opioids in renal patients with protein-energy wasting: the triaging potential of frailty. Clin. Nutr. Open. Sci. 49, 7\u201315 (2023)","journal-title":"Clin. Nutr. Open. Sci."},{"issue":"1","key":"4771_CR52","first-page":"55","volume":"34","author":"Y Narasaki","year":"2025","unstructured":"Y. Narasaki, C.M. Rhee, K. Kalantar-Zadeh, M. Rastegar, Why protein-energy wasting leads to faster progression of chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 34(1), 55\u201366 (2025)","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"11","key":"4771_CR53","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"N. Chen, C. Hao, B.C. Liu, H. Lin, C. Wang, C. Xing et al., Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl. J. Med. 381(11), 1011\u20131022 (2019)","journal-title":"N Engl. J. Med."},{"issue":"11","key":"4771_CR54","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1681\/ASN.2007020221","volume":"18","author":"KL Johansen","year":"2007","unstructured":"K.L. Johansen, G.M. Chertow, C. Jin, N.G. Kutner, Significance of frailty among dialysis patients. J. Am. Soc. Nephrol. 18(11), 2960\u20132967 (2007)","journal-title":"J. Am. Soc. Nephrol."},{"key":"4771_CR55","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s13063-015-0895-7","volume":"16","author":"A Tong","year":"2015","unstructured":"A. Tong, B. Manns, B. Hemmelgarn, D.C. Wheeler, P. Tugwell, W.C. Winkelmayer et al., Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. Trials. 16, 364 (2015)","journal-title":"Trials"},{"issue":"10075","key":"4771_CR56","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"A.C. Webster, E.V. Nagler, R.L. Morton, P. Masson, Chronic kidney disease. Lancet. 389(10075), 1238\u20131252 (2017)","journal-title":"Lancet"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04771-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04771-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04771-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:02:08Z","timestamp":1788955328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04771-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4771"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04771-9","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"294"}}